Novak at Novoste
This article was originally published in The Gray Sheet
Alfred Novak becomes president, CEO and director of the brachytherapy device manufacturer Oct. 16, succeeding Bill Hawkins, who left in January to head Medtronic's vascular unit, Medtronic AVE (1"The Gray Sheet" Dec. 24, 2001, p. 7). Novak is chairman of Orbus Medical Technologies and Transurgical, and a founding member of Syntheon LLC. He has served as president and CEO of Biosense, sold to Johnson & Johnson in 1997, from 1996 and 1998, and as CFO of Cordis from 1989 until the company was bought by J&J in 1996...
You may also be interested in...
Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.